| Symbol | ANTX |
|---|---|
| Name | AN2 THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1800 EL CAMINO REAL,SUITE D, MENLO PARK, California, 94027, United States |
| Telephone | +1 650 331-9090 |
| Fax | — |
| — | |
| Website | https://www.an2therapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Additional info from NASDAQ: |
New Form ARS - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170328 <b>Size:</b> 796 KB
Read moreNew Form DEFA14A - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170321 <b>Size:</b> 221 KB
Read moreNew Form DEF 14A - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170314 <b>Size:</b> 1 MB
Read moreNew Form EFFECT - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 9999999995-26-001256 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-164101 <b>Size:</b> 494 KB
Read moreNew Form 424B5 - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-164095 <b>Size:</b> 488 KB
Read moreAziz Kabeer 🟢 acquired 3.8K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Apr 10, 2026 | Filing ID: 151632
Read moreMarks Gilbert Lynn 🟢 acquired 3.8K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Apr 10, 2026 | Filing ID: 151628
Read moreMartin Patricia A. 🟢 acquired 1.2K shares of AN2 Therapeutics, Inc. (ANTX) Transaction Date: Apr 10, 2026 | Filing ID: 151626
Read more(99% Neutral) AN2 THERAPEUTICS, INC. (ANTX) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07024589 | First-in-Human Trial of Oral AN2-502998 | Phase1 | Healthy Volunteers | Recruiting | 2025-08-04 | 2026-04-01 | ClinicalTrials.gov |
| NCT06089668 | An Observational Study to Evaluate Clinical Characteristics of Adult Patients W… | — | Melioidosis | Completed | 2023-11-01 | 2025-02-02 | ClinicalTrials.gov |
| NCT05995444 | A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adu… | Phase1 | Healthy Volunteers | Completed | 2023-06-05 | 2023-08-03 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AN2-502998 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07024589 |
| Observational Study | OTHER | Preclinical | Melioidosis | COMPLETED | NCT06089668 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole and matching placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | DRUG | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Epetraborole | DRUG | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |